In close collaboration with Karolinska Hospital in Stockholm,  NMI in Tübingen and BILS in Umeå, NeoProteomics validates the first biomarker panel for diagnosis of ovarian cancer. The study is based on a large number of patients from Karolinska Hospital, Stockholm. Following validation, a product development of an antibody-based analysis will be initiated.